Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams sues Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics filed suit Sept. 27 in U.S. District Court for the District of New Jersey against Perrigo, alleging infringement of Adams' '252 patent for the Mucinex line of extended-release guaifenesin products. The lawsuit responds to the private labeler's filing of a Paragraph IV certification for an ANDA for a 600 mg guaifenesin tablet, equivalent to single-ingredient Mucinex, and initiates a 30-month stay, preventing FDA from approving Perrigo's product unless a court rules against Adams or that period expires (1"The Tan Sheet" Aug. 27, 2007, p. 12)...

You may also be interested in...



Adams Faces Another Mucinex Challenge, Prepares For Product Launches

Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel